
    
      The vaccine contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2
      spike protein (S). A total of 30 participants will receive the following vaccine regime:

      15 participants will receive 10^7 infectious units (IU) of MVA-SARS-2-S on days 0 and 28.

      15 participants will receive 10^8 IU of MVA-SARS-2-S on days 0 and 28. Safety and
      immunogenicity data will be collected throughout the study, which concludes at day 168.
    
  